No abstract

No abstract

Background Cardiovascular disease (CVD) is a predominant cause of mortality. Pharmacists play an important role in secondary prevention of CVD, however, their role in cardiac rehabilitation is under-reported and services are under-utilised. Aim To explore the role of pharmacists in cardiac rehabilitation, the impact of their interventions on patient outcomes, and prospects of future role development. Method Databases searched were PubMed, Embase, Medline, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and PsycINFO from January 2006 to October 2021. Randomised and non-randomised controlled trials were selected if they assessed the role of pharmacists in cardiac rehabilitation. Cochrane risk of bias tool, Joanna Briggs Institute (JBI) Critical Appraisal Tool for Quasi-Experimental Studies and the National Heart, Lung and Blood Institute (NIH) quality assessment tool, were used to assess quality and a narrative synthesis was conducted. Results The search yielded 786 studies, only five met the inclusion criteria. The pharmacist-led interventions included patient education, medication review and reconciliation, and medication adherence encouragement. Four out of the five studies showed that pharmacist-led interventions in cardiac rehabilitation significantly improved patient clinical and non-clinical outcomes. One study showed a statistically significant reduction in low density lipoprotein-cholesterol (LDL-C) levels to optimal target of < 70 mg/dL (80% vs 60%, p = 0.0084). Two studies reported better medication adherence, and two studies showed greater improvement in all domains of health-related quality of life observed in the intervention group. Conclusion Pharmacist-led interventions in cardiac rehabilitation could lower CVD risk factors and hence recurrence. Although these findings support pharmacists’ involvement in cardiac rehabilitation, larger intervention studies are needed to evaluate the feasibility of pharmacist-led interventions and their impact on hospital admissions and mortality risk.

We numerically study the evolution of spectral correlations in the entanglement Hamiltonian (EH) of noninteracting fermions in the Aubry-André-Harper (AAH) model. We analyze the time evolution of the EH spectrum in a nonequilibrium setting by studying several quantities: spectral distribution, level statistics, entanglement entropy, and spectral form factor (SFF) in the context of the delocalization-localization transition in the AAH model. It is observed that the SFF of the entanglement spectrum in the delocalized phase and at the phasetransition point evolves in three time intervals. We make a systematic study of the emergence of these three timescales for various initial states and find that the number of time intervals remains 3 unless the Hamiltonian is tuned in the localized phase or when the initial state is maximally entangled, when there is a featureless time evolution. We find a broad direct correlation between the entanglement entropy and the length of the ramp of the SFF. We also find that in the delocalized phase the spectral correlations are stronger in the center of the spectrum and grow progressively weaker as more and more of the spectrum is considered.